Chugai Pharmaceutical (OTCMKTS:CHGCY) Trading Down 10.2% - Here's What Happened

Key Points

• Chugai Pharmaceutical's stock price plummeted by 10.2%, trading as low as $22.44 before closing at $22.50.
• The company experienced a significant decline in trading volume, with only 29,199 shares exchanged compared to an average of 203,705.
• Chugai reported $0.20 earnings per share and $2.01 billion in revenue for the last quarter, showcasing a net margin of 33.08%.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report)'s share price was down 10.2% during trading on Thursday . The company traded as low as $22.44 and last traded at $22.50. Approximately 29,199 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 203,705 shares. The stock had previously closed at $25.06.

Chugai Pharmaceutical Stock Down 0.2%

The stock has a 50 day simple moving average of $24.58 and a 200 day simple moving average of $24.70. The stock has a market cap of $67.53 billion, a price-to-earnings ratio of 25.98 and a beta of 0.65.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The company reported $0.20 EPS for the quarter. The firm had revenue of $2.01 billion during the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%. Equities analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.